William Blair Issues Optimistic Forecast for VIGL Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Analysts at William Blair upped their Q2 2025 earnings per share estimates for shares of Vigil Neuroscience in a research report issued on Thursday, May 22nd. William Blair analyst M. Minter now expects that the company will earn ($0.50) per share for the quarter, up from their previous forecast of ($0.52). William Blair has a "Hold" rating on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience's Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.07) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.03) EPS.

Several other equities research analysts also recently weighed in on the company. HC Wainwright downgraded Vigil Neuroscience from a "buy" rating to a "neutral" rating and cut their price target for the stock from $14.00 to $8.00 in a report on Tuesday. JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Citigroup downgraded Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Guggenheim set a $8.00 price objective on Vigil Neuroscience and gave the company a "neutral" rating in a report on Thursday, May 22nd. Finally, Jefferies Financial Group downgraded Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $10.80.

Vigil Neuroscience Stock Down 0.1%

NASDAQ VIGL traded down $0.01 during trading hours on Monday, hitting $7.89. 597,141 shares of the company were exchanged, compared to its average volume of 649,529. The company has a 50 day moving average of $2.55 and a two-hundred day moving average of $2.39. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95. The firm has a market cap of $368.01 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently added to or reduced their stakes in VIGL. Cubist Systematic Strategies LLC boosted its position in Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after purchasing an additional 8,358 shares in the last quarter. Northern Trust Corp increased its stake in Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares during the last quarter. Barclays PLC increased its stake in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Two Sigma Investments LP increased its stake in Vigil Neuroscience by 44.0% during the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock worth $233,000 after acquiring an additional 41,836 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Vigil Neuroscience during the fourth quarter worth about $83,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.